Please assess the completion status of the following clinical trial:

Trial Title: A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria (Part 3):~* Patients should have received at least two prior treatment regimens.~* Confirmed refractory MM (measurable disease) or PCL. Patients must be refractory to treatment with both lenalidomide/dexamethasone and bortezomib/dexamethasone (or to treatment with bortezomib/lenalidomide/dexamethasone), defined as documented progressive disease on therapy or within 60 days of completing treatment with these regimens.~* Previously received adequate alkylator therapy.~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.~* Adequate hematology laboratory values without transfusion support within 2 weeks of screening.~* Adequate liver and renal function.~* Additional criteria exist.~Key Exclusion Criteria (Part 3):~* Primary amyloidosis.~* Concomitant malignancies or previous malignancies with less than a 3-year disease free interval at the time of enrollment (patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or Stage A low grade prostate cancer may enroll irrespective of the time of diagnosis).~* Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to first dose of study drug.~* Cytotoxic therapy or monoclonal antibodies within 21 days prior to first dose of study drug.~* Radiotherapy within 21 days prior to first dose of study drug (if the radiation portal covered ≤ 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy).~* Corticosteroid doses \> 10 mg/day of prednisone or equivalent within 2 weeks prior to first dose of study drug.~* Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or active hepatitis C.~* Additional criteria exist.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARRY-520 (Type: EXPERIMENTAL): None
- ARRY-520 + G-CSF support (Type: EXPERIMENTAL): None
- ARRY-520 + dexamethasone + G-CSF support (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).